Active — Not RecruitingNot Applicable

Poznan Prospective Study of Type 1 Diabetic Patients

100 participantsStarted 1994-01

Plain-language summary

The purpose of this study is to evaluate the development and progression of chronic complications (retinopathy, neuropathy, diabetic chronic renal disease, cardiovascular events) in patients with type 1 diabetes treated from the onset of the disease with recommended method of intensive insulin therapy. All patients attended a five-day structured training program during first hospitalization and re-education once year during the observation. After five years of observation and next - once a year chronic complications are assessed. The investigators would like to evaluate also the relationship of the management of the disease, knowledge about the treatment and diabetes, insulin resistance and inflammatory markers with development and progression of chronic complications.

Who can participate

Age range18 Years – 35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Newly diagnosed type 1 diabetes mellitus with features of complete insulin deficiency (serum C-peptide level \<0.05 ng/ml, acetonuria, blood gases disturbances such as: pH \<7.30, BE\< -6 mmol/l, HCO3 \<18 mmol/l) * Age \< 35 years old * Educational course in intensive insulin therapy started at the onset of the disease after treatment of ketoacidosis * Written consent Exclusion Criteria: * Uncertain type of diabetes mellitus * Kidney failure (serum creatinine level \> 1.1 mg/dl) * Liver dysfunction (AspAt \> 31 U/l, AlAt \> 34 U/l) * Acute inflammatory process * Other concomitant diseases (i.e. neoplasm)

What they're measuring

Retinopathy

Timeframe: 1 year

Diabetic chronic renal disease

Timeframe: 1 year

Neuropathy

Timeframe: 1 year

Cardiovascular events

Timeframe: 1 year

Trial details

NCT IDNCT01411033

SponsorPoznan University of Medical Sciences

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-12

View on ClinicalTrials.gov More Microangiopathy trials

Plain-language summary

Who can participate

Age range18 Years – 35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.